Game-changer for prostate cancer? AstraZeneca’s Truqap shows remarkable results in pivotal trial

AstraZeneca has announced results from its CAPItello-281 Phase III trial, revealing that Truqap (capivasertib), when combined with abiraterone and androgen deprivation therapy (ADT), significantly improves ... Read More